GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Poltreg PTG.WA · PLN

N/A · GPW · 🇵🇱 Poland

Compare

19.15

-0.26%

Close of 9 Nov 2026, in PLN

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Poltreg

Its shares trade on GPW under the ticker PTG.WA. It has been listed since 23 November 2021. In the fiscal year to 31 December 2024, it reported revenue of PLN 350,000 and a net loss of PLN 18.7m. At that date it held total assets of PLN 102.4m and shareholders' equity of PLN 69.2m.

PolTREG SA develops and commercializes patented TREG methods. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-11-23. The firm conducts research in the field of autoimmunological diseases. The firm works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The firm works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The firm is developing its own research center, which is intended as a basic location for conducting future research activities.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
23 Nov 2021
Employees
18

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • PolTreg SA employs 18 full-time staff members in Gdansk.
  • The company holds patented technology for obtaining T-regulated lymphocytes.
  • Research focuses on autoimmunological diseases like type one diabetes.

Weaknesses

  • The firm has only 18 employees, limiting operational capacity.
  • The research center is still under development and not ready.
  • Commercialization of TREG methods is not yet fully established.

Opportunities

  • Developing therapies for type two diabetes offers significant market potential.
  • Multiple sclerosis treatment research could expand the company's portfolio.
  • Cooperation with specialists enhances scientific credibility and innovation.

Threats

  • Reliance on a small team of 18 employees creates risk.
  • Long development cycles for autoimmunological disease therapies delay revenue.
  • Patent protection for TREG methods may face legal challenges.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.